Treatment Centers and Clinical Trials

You can restrict your search to only Treatment Centers or only Clinical Trials by checking the Treatment Center or Clinical Trial checkbox under TYPE. Use the Zoom-In (+ sign on the lower right of the map) to enlarge the map area to find your preferred location. To search for a Treatment Center or Clinical Trial, click on the red map pin for the name of the facility. Click on the name of the facility for more details.

Location

Treatments/Services

Treatment Centers

The Warren Alpert Medical School of Brown University, Department of Dermatology

Providence, RI, United States
Treatment Centers

University of Virginia-Emily Couric Clinical Cancer Center

Charlottesville, VA, United States
Treatment Centers

Washington University Medical Center - Siteman Cancer Center

St Louis, MO, United States
Treatment Centers

Center for Cutaneous Oncology at Dana Farber/Brigham and Women's Cancer Center

Boston, MA, United States
Treatment Centers

Columbia University Irving Medical Center - Cutaneous Lymphoma Center

New York, NY, United States
Treatment Centers

Duke Cutaneous T-Cell Lymphoma Clinic and Research Center

Durham, NC, United States
Treatment Centers

UCHealth - University of Colorado Cancer Center - Anschutz

Aurora, CO, United States
Treatment Centers

Stanford Medical Center (Multidisciplinary Cutaneous Lymphoma Clinic)

Stanford, CA, United States
Treatment Centers

Emil P. Bisaccia, MD, Center for Photopheresis at Morristown Medical Center

Morristown, NJ, United States
Clinical Trials

Lacutamab - TELLOMAK Study

An open label, multi-cohort, multi-center phase II study evaluating the efficacy and safety of lacutamab (IPH4102) alone or in combination with chemotherapy in patients with advanced t-cell lymphoma


Clinical Trial Name: IPH4102-201 / TELLOMAK study


Clinical Trial Description:

Clinical Trials

TTI-621 - Study

Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides


Brief Summary

Multicenter, open-label, phase 1a/1b trial of TTI-621 in subjects with relapsed or refractory hematologic malignancies and selected solid tumors.


Clinical Trials

Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB MF and SS

Brief Summary:

Clinical Trials

Mogamulizumab Q4week Dosing

Brief Summary:

This is an open-label, multicenter, Phase 2 study to evaluate the safety and tolerability of mogamulizumab given Q4W following initial weekly induction in adult participants with relapsed/refractory MF and SS subtypes of CTCL. The study is composed of a 28-day Screening Period during which participants are screened for entry into this study, followed by a treatment period of up to 2 years from Cycle 1 Day 1.


Clinical Trials

Dose-Escalation Trial Evaluating CPI-818

Brief Summary:

This is a Phase 1/1b, open-label, first in human study of CPI-818, an oral interleukin-2-inducible tyrosine kinase (ITK) inhibitor for the treatment of relapsed/refractory (R/R) T-cell lymphoma.. This trial will study the safety, tolerability, and anti-tumor activity of CPI-818 as a single drug. This trial is composed of dose escalation and dose expansion cohorts.


Clinical Trials

Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL

Brief Summary:

Clinical Trials

Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTC

Brief Summary:

This is an international, multicenter, multi-arm, phase Ib, model-based dose-escalation study. The primary objectives of the study in each arm is to determine the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), dose limiting toxicities (DLTs) and to evaluate the clinical efficacy at the MTD of various combinations of pembrolizumab, pralatrexate and decitabine.